Search

389 Result(s)
Sort by

Ingelvac CircoFLEX

Ingelvac CircoFLEX

For the active immunisation of pigs over the age of two weeks against porcine circovirus type 2 to reduce mortality, clinical signs – including weight loss – and lesions in lymphoid tissues associated with porcine circovirus diseases (PCVD).
Ingelvac MycoFLEX®

Ingelvac MycoFLEX®

For the active immunisation of pigs from the age of three weeks to reduce lung lesions following infections with Mycoplasma hyopneumoniae.
Ofev®

Ofev®

Ofev® is a prescription medication used to treat people with idiopathic pulmonary fibrosis (IPF) systemic sclerosis-associated interstitial lung disease (SSc-ILD) and other chronic fibrosing interstitial lung diseases with a progressive phenotype
Investment of 65 million euro in avian vaccines in France

Investment of 65 million euro in avian vaccines in France

Boehringer Ingelheim is set to invest almost €65 million in a high-tech building at its Lyon Portes-des-Alpes site in Saint-Priest, France (Rhône), to meet the growing demand worldwide for avian vaccines
Rabisin® / Raboral V-RG®

Rabisin® / Raboral V-RG®

Rabisin® is used for the active immunisation of dogs and cats to reduce mortality and clinical signs due to rabies infection.
Scam alert

Scam alert

A recruitment scam involving Boehringer Ingelheim is circulating.
STOP Rabies: moving towards elimination

STOP Rabies: moving towards elimination

Rabies still kills thousands of people every year. However, rabies is 100 percent vaccine preventable. We contribute to eliminating the disease.
environmental sustainability commitments

environmental sustainability commitments

On the occasion of the 2021 UN Climate Change Conference (COP26), Boehringer Ingelheim shares an update on its strategic approach to sustainability
Biberach

Biberach

The largest research and development center of Boehringer Ingelheim is located in Biberach, Germany.
NeO - smart and sustainable vaccines

NeO - smart and sustainable vaccines

The reduction in the environmental impact of the new NeO vaccine packaging illustrates Boehringer Ingelheim’s drive for environmental responsibility.
Vienna

Vienna

Vienna is a cornerstone within the company’s global R&D network, with a special focus on cancer research. On top of that, it is also a hub for biopharmaceutical development and production.
Transforming Science Day

Transforming Science Day

How our ‘patient first’ approach to innovation is aiming to accelerate breakthrough therapies that transform lives. Join our Transforming Science Day.